Drugs / XT1061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06280534 | Jul 2023 → Feb 2024 | chronic hepatitis B virus infection | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XT1061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280534 ↗ |